3rd Quarter 2025 Financial Results & Investor Day October 28, 2025 Legal Disclaimers This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Forward- looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financ ...

Core Insights - U.S. stocks experienced an upward trend, with the Dow Jones index increasing by approximately 200 points on Tuesday [1] Company Performance - Wayfair Inc reported third-quarter earnings of 70 cents per share, surpassing the analyst consensus estimate of 43 cents per share, and quarterly sales of $3.117 billion, exceeding the consensus estimate of $3.014 billion, leading to a 21.8% surge in shares to $105.40 [1] - Arcutis Biotherapeutics Inc shares rose by 23.5% to $24.26 following strong quarterly results [4] - Terawulf Inc gained 20% to $16.37 after reporting preliminary third-quarter 2025 financial results [4] - Cameco Corp shares surged 19.3% to $103.33 due to a partnership with Brookfield and the U.S. government for new Westinghouse nuclear reactors [4] - Agilysys Inc saw a 16.3% increase to $133.86 after reporting upbeat quarterly earnings [4] - Leggett & Platt Inc shares surged 13.6% to $10.46 following strong quarterly sales [4] - Nanobiotix SA – ADR gained 15.5% to $17.42 [4] - Skyworks Solutions Inc shares increased by 14.2% to $86.59 after announcing a merger agreement with Qorvo [4] - Qorvo Inc shares jumped 11.8% to $103.00 in light of the merger agreement with Skyworks [4] - PayPal Holdings Inc rose 11.1% to $78.05 after announcing a deal with OpenAI and releasing better-than-expected third-quarter financial results [4] - Confluent Inc reported better-than-expected earnings for the third quarter, leading to a 10.9% rise in shares to $24.50 [4] - ATI Inc gained 10.4% to $101.28 after reporting better-than-expected quarterly financial results [4] - Celestica Inc shares increased by 8.7% to $328.00 after better-than-expected quarterly results and raised FY2025 EPS and sales guidance [4] - United Parcel Service Inc rose 8.1% to $96.42 after reporting better-than-expected third-quarter results and issuing above-estimate fourth-quarter sales guidance [4] - Regeneron Pharmaceuticals Inc shares surged 7.6% to $629.57 following better-than-expected quarterly results [4] - Check Point Software Technologies Ltd gained 7% to $205.28 after reporting better-than-expected quarterly results [4] - Nucor Corp shares increased by 6.1% to $152.88 after posting better-than-expected earnings for the third quarter [4]

Product Development and Approvals - ZORYVE cream 0.3% was launched in August 2022 and received FDA approval for expanded indications down to 6 years of age in October 2023[122]. - ZORYVE foam for seborrheic dermatitis was approved by the FDA in December 2023 and became commercially available in January 2024[122]. - A co-promotion agreement with Kowa Pharmaceuticals was established in July 2024 to market ZORYVE in the U.S. until at least July 2029[124]. - The company halted further development of ARQ-255 after completing a Phase 1b study in mid-2025[125]. - The company plans to commence a Phase 1 study of ARQ-234 in the first quarter of 2026 after submitting an IND application in July 2025[126]. Financial Performance - The company reported net losses of $33.5 million and $129.3 million for the nine months ended September 30, 2025 and 2024, respectively, with an accumulated deficit of $1,155.5 million as of September 30, 2025[127]. - Product revenue for ZORYVE cream 0.3% increased by $8.5 million, or 38%, to $30.5 million for the three months ended September 30, 2025, compared to the same period in 2024[146]. - ZORYVE foam revenue surged by $29.5 million, or 146%, reaching $49.8 million for the three months ended September 30, 2025, driven by higher demand and new product launches[148]. - Total product revenue for the three months ended September 30, 2025, was $99.2 million, a 122% increase from $44.8 million in the same period of 2024[146]. - For the nine months ended September 30, 2025, total product revenue reached $244.6 million, a 152% increase from $97.2 million in the same period of 2024[157]. - ZORYVE cream 0.15% revenue increased by $41.3 million, or 1686%, for the nine months ended September 30, 2025, driven by its commercial launch in July 2024[160]. Expenses and Cash Flow - The company expects to incur significant commercialization expenses related to ZORYVE and product candidates, while focusing on clinical development for ARQ-234 and ZORYVE label expansions[128]. - Selling, general and administrative expenses are anticipated to increase as the company continues to commercialize ZORYVE and support operations[140]. - Research and development expenses slightly increased by $0.1 million, or 1%, totaling $19.6 million for the three months ended September 30, 2025[152]. - Selling, general and administrative expenses rose by $3.6 million, or 6%, to $63.5 million for the three months ended September 30, 2025, primarily due to commercialization efforts[153]. - The company expects research and development expenses to increase in future periods due to ongoing development and clinical studies related to ARQ-234 and ZORYVE life cycle management[165]. - For the nine months ended September 30, 2025, net cash used in operating activities was $31.8 million, compared to $111.4 million for the same period in 2024[185][187]. - During the nine months ended September 30, 2025, net cash provided by investing activities was $3.9 million, primarily from maturities of marketable securities totaling $172.4 million[188]. Debt and Interest Rates - As of September 30, 2025, the aggregate principal amount outstanding under the Loan Agreement was $100.0 million[174]. - The company made a 2024 Partial Prepayment of $100.0 million, reducing the outstanding principal under the Loan Agreement and incurring a prepayment penalty of $1.0 million[175]. - The applicable interest rate after the 2024 Partial Prepayment is 5.95% plus the greater of 2.50% or the one-month Secured Overnight Financing Rate (SOFR)[176]. - The company has $100.0 million outstanding under its Loan Agreement, with a floating interest rate of 5.95% plus the greater of 2.50% or the one-month SOFR[195]. - A 100 basis point increase in interest rates would result in approximately $1.0 million of additional annual interest expense for the company[195]. - The maturity date of the Loan Agreement is August 1, 2029, following the 2024 Partial Prepayment[175]. Cash and Securities - As of September 30, 2025, the company had cash, cash equivalents, restricted cash, and marketable securities totaling $191.4 million[127]. - As of September 30, 2025, the company had cash and cash equivalents of $47.1 million, restricted cash of $0.3 million, and marketable securities totaling $143.9 million[194]. Foreign Currency and Risk Management - The company is exposed to foreign currency exchange risk due to its Canadian subsidiary operating in Canadian dollars, with cash balances of $6.4 million in Canadian dollars as of September 30, 2025[196]. - The company does not currently engage in hedging transactions for interest rate or foreign currency risks[195][196]. - A hypothetical 10% change in foreign exchange rates would not have a material impact on the company's condensed consolidated financial statements[196]. - An immediate change in interest rates of 100 basis points would not materially affect the fair value of the company's investment portfolio due to its low risk profile[194].

Financial Performance - Q3 2025 net product revenue for ZORYVE was $99.2 million, a 122% increase compared to Q3 2024, and a 22% increase compared to Q2 2025[4] - ZORYVE net product sales for Q3 2025 were $99.2 million, driven by increasing demand and improved gross-to-net pricing[8] - Product revenue for Q3 2025 reached $99.219 million, a significant increase from $44.755 million in Q3 2024, representing a growth of 121%[27] - Total revenues for the nine months ended September 2025 were $246.569 million, compared to $125.182 million for the same period in 2024, marking a 97% increase[27] - Net income for Q3 2025 was $7.4 million, compared to a net loss of $41.5 million in Q3 2024[16] - Net income for Q3 2025 was $7.410 million, a recovery from a net loss of $41.537 million in Q3 2024[27] - Basic earnings per share for Q3 2025 were $0.06, compared to a loss of $0.33 per share in Q3 2024[27] Expenses - Research and development expenses for Q3 2025 were $19.6 million, consistent with the previous year[14] - Selling, general, and administrative expenses for Q3 2025 were $62.4 million, an increase from $58.8 million in Q3 2024[15] - Operating expenses for Q3 2025 totaled $90.693 million, up from $83.821 million in Q3 2024, reflecting an increase of 8%[27] - Research and development expenses for the nine months ended September 2025 were $56.600 million, down from $61.940 million in the same period of 2024, a decrease of 9%[27] - Selling, general, and administrative expenses increased to $62.404 million in Q3 2025 from $58.817 million in Q3 2024, an increase of 4%[27] - Interest expense for the nine months ended September 2025 was $9.082 million, down from $21.617 million in the same period of 2024, a reduction of 58%[27] - The company reported other income of $2.035 million in Q3 2025, compared to $4.182 million in Q3 2024, a decrease of 51%[27] Product Development - ZORYVE cream 0.05% received FDA approval for treating atopic dermatitis in children as young as 2 years old in October 2025[4] - The company provided initial 2026 full year net product sales guidance of $455–$470 million[17] - ZORYVE is projected to achieve peak sales of $2.6–$3.5 billion annually across current and potential future indications[7] - The company is preparing to initiate a Phase 1 study of ARQ-234, a potential biologic treatment for atopic dermatitis[9] Cash and Securities - Cash, cash equivalents, and marketable securities totaled $191.4 million as of September 30, 2025, down from $228.6 million at the end of 2024[16] - The weighted-average diluted shares used in computing earnings per share for Q3 2025 were 132,885 thousand, unchanged from Q3 2024[27]

Core Insights - Arcutis Biotherapeutics, Inc. is focused on sustainable growth through its innovative dermatology products, particularly the ZORYVE franchise, which has shown significant commercial momentum [2][5][6] Financial Performance - For Q3 2025, Arcutis reported net product revenue of $99.2 million, marking a 122% increase year-over-year and a 22% increase sequentially from Q2 2025 [5][7][9] - The revenue breakdown includes $30.5 million from ZORYVE cream 0.3%, $18.9 million from ZORYVE cream 0.15%, and $49.8 million from ZORYVE topical foam 0.3% [9] - The company anticipates full-year net product sales for 2026 to be between $455 million and $470 million [14] Product Development and Pipeline - ZORYVE is a potent PDE4 inhibitor approved for treating plaque psoriasis, atopic dermatitis, and seborrheic dermatitis, with ongoing Phase 2 studies for vitiligo and hidradenitis suppurativa [3][4][6] - The company is also advancing its clinical pipeline with ARQ-234, a potential biologic treatment for atopic dermatitis [8] Cost and Expenses - Cost of sales for Q3 2025 was $8.7 million, up from $5.5 million in Q3 2024, reflecting increased sales of ZORYVE [10] - Research and development expenses remained stable at $19.6 million, while selling, general, and administrative expenses rose to $62.4 million due to increased commercialization efforts [11][12] Profitability - Arcutis achieved a net income of $7.4 million, or $0.06 per share, compared to a net loss of $41.5 million in Q3 2024 [13][24]

Core Insights - Arcutis Biotherapeutics announced new data on ZORYVE® (roflumilast) cream, showing improvements in quality of life for atopic dermatitis patients, particularly in reducing sleep disruptions and providing long-term disease control for individuals aged 2 years and older [1][2][5] Clinical Data - ZORYVE cream demonstrated significant improvements in sleep and itch reduction in patients aged 2 to 5 years and 6 years and older, based on patient-reported outcomes from three Phase 3 trials [3][6] - The treatment was well-tolerated, with adverse events reported in ≤6% of patients, and serious adverse events in <1% [6][12] Long-term Efficacy - Long-term data from the INTEGUMENT-OLE trial indicated that ZORYVE cream maintained or improved disease control over 56 weeks, with a notable percentage of patients achieving 'Clear' or 'Almost Clear' status [8][12] - The median duration of disease control for patients switching to twice-weekly treatment was 238 days for children aged 2-5 and 281 days for older patients [12] Product Recognition - ZORYVE has received multiple awards, including the "2025 Best of Beauty Breakthrough Award" from Allure and the National Psoriasis Foundation's Seal of Recognition, highlighting its clinical impact and industry recognition [10] Indications and Usage - ZORYVE cream is indicated for the topical treatment of mild to moderate atopic dermatitis in pediatric patients aged 2 to 5 years and in patients aged 6 years and older [11][13]

Core Insights - The FDA has approved Arcutis Biotherapeutics' ZORYVE (roflumilast) cream 0.05% for treating mild to moderate atopic dermatitis in children aged 2 to 5 years, providing a steroid-free alternative for long-term use [1][6][23] - Approximately 1.8 million children in the U.S. aged 2 to 5 are treated for atopic dermatitis, highlighting a significant market need for effective treatments [2][6] - ZORYVE cream demonstrated rapid and significant improvements in clinical trials, with 40% of children achieving a 75% improvement in eczema symptoms within four weeks [2][12] Company Overview - Arcutis Biotherapeutics is focused on developing innovative treatments for immune-mediated dermatological diseases, with a growing portfolio of advanced topical therapies [30] - The approval of ZORYVE cream 0.05% marks the sixth FDA approval for the ZORYVE product line in just over three years, indicating strong regulatory momentum [1][6] - The company aims to ensure predictable access to ZORYVE through patient support programs, including the ZORYVE Direct Program and Arcutis Cares™ for financially eligible patients [4][30] Clinical Data - The FDA approval was based on results from the INTEGUMENT-PED Phase 3 trial, which involved 652 children and demonstrated rapid disease clearance and safety [10][11] - In the INTEGUMENT-PED trial, 25.4% of children treated with ZORYVE achieved a 'Clear' or 'Almost Clear' status by Week 4, compared to 10.7% in the vehicle group [12] - The long-term extension study (INTEGUMENT-OLE) showed that 71.9% of participants maintained a 75% improvement in eczema severity after 56 weeks of treatment [16] Market Context - Atopic dermatitis affects approximately 9.6 million children in the U.S., with a significant impact on family life due to sleep disruption and emotional distress [19][20] - ZORYVE is positioned as a leading topical therapy for atopic dermatitis, with recognition from industry awards, including Allure's "2025 Best of Beauty Breakthrough Award" [22][21] - The product's formulation targets underlying inflammation without compromising the skin barrier, making it particularly suitable for young children [3][21]

Core Viewpoint - Arcutis Biotherapeutics, Inc. (ARQT) has experienced significant stock performance, with a 23% increase over the past month and a 35.3% gain since the beginning of the year, outperforming the Zacks Medical sector and the Zacks Medical - Biomedical and Genetics industry [1][3]. Financial Performance - The company has a strong record of positive earnings surprises, having beaten earnings consensus estimates in the last four quarters. In the latest earnings report on August 6, 2025, Arcutis reported an EPS of -$0.13, surpassing the consensus estimate of -$0.18, and beat the revenue estimate by 12.32% [2]. - For the current fiscal year, Arcutis is expected to post earnings of -$0.46 per share on revenues of $329.85 million, reflecting a 60.34% change in EPS and a 67.83% change in revenues. For the next fiscal year, the company is projected to earn $0.10 per share on revenues of $430.73 million, indicating a year-over-year change of 121.2% in EPS and 30.58% in revenues [3]. Valuation Metrics - Despite being at a 52-week high, the future valuation metrics are crucial for assessing potential stock performance. The Zacks Style Scores provide insights into various investment styles, with Arcutis having a Value Score of D, a Growth Score of A, and a Momentum Score of C, resulting in a VGM Score of B [4][6]. Zacks Rank - Arcutis Biotherapeutics holds a Zacks Rank of 2 (Buy), supported by a solid earnings estimate revision trend. This rank is considered more significant than the VGM Score, indicating a favorable outlook for the stock [7][8].

Core Viewpoint - Arcutis Biotherapeutics, Inc. will report its third quarter 2025 financial results on October 28, 2025, and will host a virtual Investor Day to discuss these results and other strategic initiatives [1][2]. Company Overview - Arcutis Biotherapeutics is a commercial-stage medical dermatology company focused on innovative solutions for immune-mediated dermatological diseases, with a portfolio of advanced targeted topicals approved for three major inflammatory skin diseases [3]. - The company utilizes a unique dermatology development platform and expertise to create differentiated therapies targeting biologically validated conditions, resulting in a robust pipeline for various inflammatory dermatological issues [3]. Upcoming Events - The Investor Day will include presentations from the management team and a fireside chat with Douglas DiRuggiero, PA-C, DMSc, highlighting the company's strategy and clinical advancements [1][5]. - A Q&A session will follow the formal presentations, and a live webcast will be available on the company's website, with an archived replay posted afterward [2]. Strategic Focus - The event will provide an in-depth look into the company's long-term growth strategy for ZORYVE® (roflumilast), clinical development activities for new indications, and an overview of the capital allocation strategy and financial outlook [5].

Group 1 - Arcutis Biotherapeutics (ARQT) is currently breaking out past two buy points, making it a top stock to watch in the S&P 500 for 2025 [1] - The company specializes in developing dermatology treatments for immune-related skin diseases and conditions, with its main product Zoryve foam approved by the U.S. FDA [1] - The Dow Jones index was flat as President Trump prepared for shutdown talks, while stocks like EA, Nvidia, and Tesla experienced rallies [2] Group 2 - Palantir is facing competition from Lockheed Martin as it aims for significant growth in the S&P 500, being noted as the index's biggest winner in 2025 [4] - The market is currently influenced by AI and gold, which are yielding substantial winners, with several stocks joining the IBD 50 list [4] - Despite a recent decline in indexes, stocks like Nvidia and Palantir are nearing buy points, with upcoming Fed inflation data expected to impact market movements [4]